This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacob, P. Articles by Benowitz, N. L. Search for Related Content PubMed PubMed Citation Articles by Jacob, P., III Articles by Benowitz, N. L.

Anabasine and Anatabine as Biomarkers for Tobacco Use during Nicotine Replacement Therapy¹

Division of Clinical Pharmacology, San Francisco General Hospital Medical Center, Department of Medicine [P. J., L. Y., N. L. B.], Drug Dependence Research Center [P. J.], and Department of Psychiatry [S. H.], University of California, San Francisco, San Francisco, California 94110; Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota 55414 [D. H.]; and Pacific Research Institute, Eugene, Oregon 97403 [H. S.]

In this study we determined urine concentration of the tobacco alkaloids anabasine and anatabine, nicotine and its metabolites cotinine, and nornicotine in 99 cigarette smokers and 205 smokeless tobacco users. We also investigated the possibility that anabasine and anatabine can be used as biomarkers for tobacco use during nicotine replacement therapy.

Urine samples and data on self-reported tobacco use were obtained from subjects enrolled in tobacco cessation programs. Urine concentrations of tobacco alkaloids and metabolites were measured and correlated with self-reported tobacco use. Concentrations of anabasine and anatabine were used to validate abstinence in smokeless tobacco users who used nicotine gum as part of the therapy.

Correlations of alkaloid concentration with self-reported tobacco use before treatment ranged from fair to poor. In subjects abstaining from smokeless tobacco but using nicotine gum, anabasine and anatabine levels were below the cut-point of 2 ng/ml despite high concentrations of nicotine and cotinine resulting from nicotine gum use.

Anabasine and anatabine concentrations in urine can be used to validate abstinence or measure the extent of tobacco use in persons undergoing nicotine replacement therapy.

This article has been cited by other articles:

				D. K. Hatsukami, M. Kotlyar, S. Allen, J. Jensen, S. Li, C. Le, and S. Murphy Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures Chest, October 1, 2005; 128(4): 2528 - 2537. [Abstract] [Full Text] [PDF]

				S. E. Murphy, C. A. Link, J. Jensen, C. Le, S. S. Puumala, S. S. Hecht, S. G. Carmella, L. Losey, and D. K. Hatsukami A Comparison of Urinary Biomarkers of Tobacco and Carcinogen Exposure in Smokers Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1617 - 1623. [Abstract] [Full Text] [PDF]

				D. K. Hatsukami, C. Lemmonds, Y. Zhang, S. E. Murphy, C. Le, S. G. Carmella, and S. S. Hecht Evaluation of Carcinogen Exposure in People Who Used "Reduced Exposure" Tobacco Products J Natl Cancer Inst, June 2, 2004; 96(11): 844 - 852. [Abstract] [Full Text] [PDF]

				S. S. Hecht, S. G. Carmella, K.-A. Le, S. E. Murphy, Y. S. Li, C. Le, J. Jensen, and D. K. Hatsukami Effects of Reduced Cigarette Smoking on Levels of 1-Hydroxypyrene in Urine Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 834 - 842. [Abstract] [Full Text] [PDF]

				S. S. Hecht, S. E. Murphy, S. G. Carmella, C. L. Zimmerman, L. Losey, I. Kramarczuk, M. R. Roe, S. S. Puumala, Y. S. Li, C. Le, et al. Effects of Reduced Cigarette Smoking on the Uptake of a Tobacco-Specific Lung Carcinogen J Natl Cancer Inst, January 21, 2004; 96(2): 107 - 115. [Abstract] [Full Text] [PDF]

				J. D. Anczak and R. A. Nogler II Tobacco Cessation in Primary Care: Maximizing Intervention Strategies Clin. Med. Res., July 1, 2003; 1(3): 201 - 216. [Abstract] [Full Text] [PDF]